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Background: Alzheimer’s disease and other related dementias are public health priorities in the European Union
due to their prevalence, cost and profound impact on society. Because of these pressing implications, the European
Union decided to create a Joint Action to share knowledge about dementia and health policy in order to preserve
the health, quality of life, autonomy and dignity of people living with dementia and their carers in Europe.
Methods: ALCOVE is a European Community-funded Joint Action coordinated by the HAS (French National
Authority for Health) with a 24-month duration. The project’s life cycle has been divided into the following four
steps: (1) collection of existing information, (2) analysis of existing information and making comparisons across
Member States, (3) identifying Evidence, Needs, and Priorities, (4) drafting recommendations and disseminating
them.
Results: 19 countries are participating in the ALCOVE initiative. The project will publish its final findings in 2013.
The project’s objectives, participants, method, on-going procedures and work plans are already available on the
ALCOVE website: http://www.alcove-project.eu/. Preliminary results show that recommendations will need to focus
on clinical and epidemiological data collection, diagnostic system assessment, outstanding approaches for treating
behavioural disorders, limiting antipsychotic use, and competence assessment in this vulnerable population.
Conclusions: The European Member States involved are mobilized to share best health policy practices in order to
tackle the challenge of dementia’s threat on European health and social systems and to improve the quality of life
and care for individuals and their family carers.
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Prevalence, Diagnosis, Advanced declaration of will, Health care systemBackground
The last 50 years in Europe have seen an overall dra-
matic increase in life expectancy, with a corresponding
rise in the incidence of diseases linked to aging such
as dementia [1,2]. More than 7 million Europeans are
directly affected by dementia, the most common form
being Alzheimer’s disease which is characterised by* Correspondence: c.barr@has-sante.fr
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reproduction in any medium, provided the orprogressive memory loss and cognitive troubles as well
as the occurrence of disturbing behaviour disorders
[3,4]. Alzheimer’s disease and related dementias are
public health priorities in EU Member States due to
their prevalence, cost and profound impact on society
[5-9].
ALCOVE is a European Community-funded Joint Ac-
tion (JA) coordinated by the HAS (French National Au-
thority for Health), with the participation of 19
European Member States (MS) and involving 30 partner
organisations (Figure 1, Additional file 1: Annex 1). The. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 European Union Joint Action ALCOVE. (Alzheimer COoperative Valuation in Europe), 19 participating countries.
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governments for their clinical, epidemiological or public
health expertise in Alzheimer’s disease and related
dementias.
The project aims to share knowledge about dementia
and to preserve the health, quality of life, and the auton-
omy and dignity of people living with the disease and
their carers in European Union Member States. To this
end, the ALCOVE project aims to establish a sustainable
European network (1) to provide better care and services
all along the progression of Alzheimer’s disease and
related dementia from early diagnosis to home or insti-
tutionalized care, including reduction in the risk related
to the use of antipsychotics [10-13]; (2) to exchange
experiences and knowledge about dementia health policy
[13-15]; and (3) to inform and advise decision-makers,
healthcare professionals, carers, and citizens.
The goal of the ALCOVE-Joint Action is to reply to
the following strategic questions in order to guide public
health decisions in EU Member States by fostering better
coordination of the management of care for peopleliving with Alzheimer’s Disease (AD) and other related
dementias:
1. How to improve data for better knowledge about
dementia prevalence?
2. How to improve access to a dementia diagnosis and,
in the process, to the appropriate care as early as
possible?
3. How to improve care for people living with dementia
and particularly those exhibiting the Behavioural and
Psychological Symptoms of Dementia (BPSD)?
4. How to improve the rights of people with dementia
regarding advance declarations of will and
competence assessments?
The use of antipsychotics in this vulnerable population
has been chosen as a common ground for the 4 core
questions and as a guide to support the implementation
of good practices in the field of risk prevention asso-
ciated with the use of psychotropic drugs in people liv-
ing with dementia [12,13,16].
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ALCOVE is an operational public health project with a
24-month duration. The project’s life cycle has been
divided into four steps as described below. ALCOVE is
currently working on steps 1 and 2 and has already
begun collecting the existing information on available
epidemiological data in Europe and on the most recent
scientific findings regarding good practices in the care of
individuals living with Alzheimer’s disease and related
dementia. The project’s next steps will be to identify and
prioritize the needs of people living with Alzheimer’s
disease and related dementia and to issue recommen-
dations on how to best address these needs. The
process that ALCOVE is following is highlighted in
Figure 2 [17].
1. Collection of existing informationFigALCOVE’s method entails reviewing recent scientific
literature, with an explicit strategy: period and terms
of research, sources of information [Automated
bibliographic databases; Medline (National Library of
Medicine, United States), the Cochrane Library
(Wiley Interscience, United States), OVID, In-Process
& Other Non-Indexed Citations and Ovid
MEDLINE; Pascal; CLEIRPPA database (FNG),
French National Geriatrics; National Guidelineure 2 ALCOVE Collaborative Method.Clearinghouse (United States); HTA Database
(International Network of Agencies for Health
Technology Assessment - INAHTA), Guidelines
International Network]. Additionally, a grey literature
search was conducted to identify Alzheimer Plans
that have been implemented at the national level and
evaluations of such plans. To this end, the project
has consulted and used relevant websites, such as
those of learned institutions specializing in the
studied field, as well as the bibliographies of the
selected articles and documents.
This literature review is being combined with the use
of ALCOVE-designed questionnaires (Additional file
2: Annex 2) to collect relevant information from
principal actors in the field such as National Health
Ministries, Physicians, Geriatricians, and Memory
Clinics as well as National Health Registries and
databases.
2. Analysis of existing information and making
comparisons across Member States
ALCOVE’s first aim is to improve data for better
knowledge about dementia: the research is focused
on prevalence rates for Alzheimer’s disease and
related dementia in Europe and the evaluation of the
rate of exposure of Europeans living with dementia
to antipsychotics.
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the timely access to a dementia diagnosis, ALCOVE
will compare national recommendations for a timely
diagnosis in order to establish a common definition.
ALCOVE will investigate the organisation of
diagnostic systems within Member States and the
localisation and availability of Memory Clinics while
examining the role of General Practitioners and
strategies for a timely diagnosis in Primary Care,
including nursing/retirement homes.
In order to improve care for people living with
dementia, and particularly those experiencing
behavioural disorders, ALCOVE will identify the
existing support systems for those exhibiting BPSD,
specifically focusing on innovative and/or efficient
measures in limiting the prescription of
antipsychotics to treat BPSD, which have recently
been shown to be non- effective and deleterious for
these patients [12,13].
ALCOVE will analyze the current education that
health care personnel who work with patients
exhibiting BPSD receive and highlight areas where
this education could be enriched. Furthermore,
ALCOVE will be collecting data on the procedures
currently in place for the prescription of
antipsychotics (the majority have an off- label use) in
clinical practice within European countries.
Within the context of ALCOVE’s fourth question
regarding improving the autonomy of individuals
living with Alzheimer’s disease and related dementia,
the project will be identifying the existing national
regulations on advance directives of will and
informed consent, investigating the possibility of
moving towards a more coordinated European
perspective, describing how advance directives and
informed consent are used in practice for people
living with Alzheimer’s disease and related dementia,
and identifying the good practices for competence
assessment while documenting how the prescription
of antipsychotic drugs could affect their validity.
3. Evidence, needs, and priorities
Based on the analyses and the answers to the four
main questions, attained through the combination of
literature searches, and the analyses of evidence and
assessed practices or systems, ALCOVE will be able
to both identify (a) the systems or practices devoted
to dementia in place in the different European Union
Member States, including how much they differ or
vary from one another; and (b) the good practices
and support systems which could be promoted at the
European level.
4. Recommendations and Dissemination
Finally, ALCOVE will be making recommendations
concerning good practices in epidemiological datacollection, in the organisation of health systems or
services for an earlier diagnosis, in the support
systems and educational programmes for preventing
BPSD and the overuse of antipsychotics, in
competence assessment and the drafting of advanced
declarations of will for this population.Dissemination of our findings and analyses will be
assured by a dedicated website, public and scientific con-
ferences, professional publications and cooperation with
other international referent networks.
Results and discussion
The ALCOVE JA is an on-going project that will not
publish its findings until 2013. As such, it is not generat-
ing original research, but rather is analyzing recent sci-
entific findings and current treatment and care realities
in Europe so that recommendations can be generated
for good practices in diagnosing and treating individuals
living with Alzheimer’s disease and related dementia,
both at a theoretical and scientific level. The project’s
objectives, participants, method and on-going proce-
dures and workplans are already available on the AL-
COVE website: (http://www.alcove-project.eu/).
ALCOVE preliminary results show:
(1) That currently there is a discrepancy between the
observed rate of prevalence in the national health
systems, when this data is available, and the
observed rate in cohorts. An updated mapping of
different sources such as national insurance
databases, registries, cohorts, surveys and
recommendations to improve the quality and
coherence of data collection could contribute to a
better knowledge of the prevalence of Alzheimer’s
disease and related dementia, which is crucial in the
construction of relevant strategies. [5,6]
(2) That Alzheimer’s disease and related dementia are
under-diagnosed all across European Union
Member States. At this stage, improving diagnosis
quality means making a timely diagnosis of the
disease. Several European countries have already
been working with memory centres for 10 years and
the first appraisals of their effectiveness are now
available. [18,19]
(3) That delivering better care in the treatment of
BPSD is a shared and high level priority. BPSD is a
large burden for daily carers and health
professionals, so much so that it is a major reason
behind early institutionalisation and/or the
prescribing of antipsychotics. Currently, new non-
pharmaceutical interventions are being implemented
in an effort to reduce BPSD and their consequences,
such as targeted care techniques and psychological
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these non-pharmaceutical approaches is still on-
going. [14,20-24]
(4) Various and heterogeneous legal dispositions for
people living with dementia are available in
European Union Member States. An important
question is how to find a better balance between
preserving autonomy while legally protecting the
individual (driving licence, will). Health
professionals need dedicated information and
training on good practices for competence
assessment in people living with dementia. [25-31]
(5) ALCOVE’s participants have decided that a special
focus will be made on the inappropriate use of
antipsychotics to treat the BPSD of Alzheimer’s
disease and related dementia as this is an urgent
issue affecting patient safety and the quality of life of
individuals living with dementia and their carers
[12-14,16] As the culmination of the project,
ALCOVE will provide information on the exposure
of patients living with dementia to antipsychotics in
Europe and an evaluation of the existing
antipsychotics risk reduction strategies for people
living with dementia.
An operational set of improvement tools and methods
(information support, indicators, professional programmes,
clinical guidelines, etc) based on the European bench-
marking performed by ALCOVE will be proposed and
will be available on ALCOVE website (http://www.
alcove-project.eu/).
Conclusion
ALCOVE’s partners and work package leaders share the
concrete goal of ensuring patient safety and quality of
life for individuals living with Alzheimer’s disease and
other dementias in Europe. An important element of
this goal and the tie that binds the work being com-
pleted by all of those involved is a focus on reducing the
overexposure to antipsychotic drugs among individuals
living with dementia. In compiling the most recent re-
search and evidence of good practices already imple-
mented in the care of dementia, it is ALCOVE’s mission
to share this information so that Europeans living with
Alzheimer’s disease will have access to new care options
from which they will benefit.
By promoting the best options in Alzheimer’s disease
care and providing a toolbox of care options, ALCOVE
will help European Member States reduce the risks
involved in the use of antipsychotic medications to treat
BPSD, promote alternative treatments, and alert and
educate carers so that they will be better equipped and
more supported when caring for individuals living with
Alzheimer’s disease.Endnote
ALzheimer COoperative Valuation in Europe.
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